Lilly(US:LLY) 生物世界·2026-02-10 01:18Core Viewpoint - Eli Lilly announced the acquisition of Orna Therapeutics for up to $2.4 billion, marking a significant move into the in vivo CAR-T therapy space [3][8]. Group 1: Acquisition Details - The acquisition price of $2.4 billion includes both upfront payments and milestone payments related to clinical development [3]. - Orna Therapeutics is recognized as the first company globally to develop new therapies using engineered circRNA [5]. Group 2: Orna Therapeutics' Innovations - Orna is advancing a new therapy that combines engineered circRNA with novel lipid nanoparticles (LNP) to generate CAR-T cells in vivo, targeting diseases such as B-cell driven autoimmune disorders [6]. - The lead project, ORN-252, is a clinical trial-ready in vivo CAR-T therapy targeting CD19 [6]. Group 3: Industry Context - Eli Lilly's acquisition aligns with recent trends in the industry, where companies like Gilead Sciences and AbbVie have also made significant investments in in vivo CAR-T technologies [8]. - The acquisition is part of Eli Lilly's broader strategy to leverage cash flow from GLP-1 weight loss drugs for further investments in innovative therapies [11].